Ipsen (FRA:I7G) Debt-to-Equity : 0.08 (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Ipsen Debt-to-Equity?

Ipsen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €36 Mil. Ipsen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €270 Mil. Ipsen's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €3,825 Mil. Ipsen's debt to equity for the quarter that ended in Dec. 2023 was 0.08.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Ipsen's Debt-to-Equity or its related term are showing as below:

FRA:I7G' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.2 Max: 0.58
Current: 0.08

During the past 13 years, the highest Debt-to-Equity Ratio of Ipsen was 0.58. The lowest was 0.01. And the median was 0.20.

FRA:I7G's Debt-to-Equity is ranked better than
75.3% of 826 companies
in the Drug Manufacturers industry
Industry Median: 0.27 vs FRA:I7G: 0.08

Ipsen Debt-to-Equity Historical Data

The historical data trend for Ipsen's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ipsen Debt-to-Equity Chart

Ipsen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.58

0.41

0.25

0.18

0.08

Ipsen Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Equity	Get a 7-Day Free Trial															0.24	0.18	0.15	0.08	N/A

Competitive Comparison of Ipsen's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Ipsen's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ipsen's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ipsen's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Ipsen's Debt-to-Equity falls into.

Ipsen Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Ipsen's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(36.4	+	269.7)	/	3825.1
	=	0.08

Ipsen's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(36.4	+	269.7)	/	3825.1
	=	0.08

Ipsen (FRA:I7G) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Ipsen Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Ipsen's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Ipsen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipsen SA (FRA:I7G) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

IPSEY:USA IPSEF:USA IPNp:UK 0MH6:UK IPN:France

Address

65 Quai Georges Gorse, Billancourt Cedex, Boulogne, FRA, 92100

Website

https://www.ipsen.com

Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.

Ipsen Headlines

No Headlines